Clinical Observasion of Interferon in the Retreatment of 32 Patients with Chronic Hepatitis C

李晓娟,于岩岩,斯崇文

DOI: https://doi.org/10.3969/j.issn.2095-3402.2004.02.011

2004-01-01

Abstract:Objective To evaluate the effect of previous nonresponders or relapsers of chronic hepatitis C with consensus interferon and observe the adverse events. Methods 32 patients who are previous nonresponders or relapsers to IFN received CIFN 15 μg three times a week for 24 weeks,efficacy assessments consist of symptoms,physical signs,ALT and HCV RNA in the treatment period and at week 12 and 24 of the treatment-free period. Safety assessments consist of clinical and laboratory evaluations. Results 31 patients completed full course of treatment. After 24 weeks treatment,HCV RNA negative rate in nonresponders and relapsers were 90% versus 45.45%( P 0.05).After 24 weeks follow up,HCV RNA negative rate were 70.58% versus 20%( P 0.05).The effect of previous relapsers were better than that of previous nonresponders. ALT in pretreatment had no effect to end of response rate (P 0.05). There was a significant statistical difference in the ETR rate between the patients whose HCV RNA became negative at 12 week and the patients whose were still positive. The major adverse events were fever,leukopenia,neutrophilic granulocytopenia and thrombocytopenia. The mean time of leukopenia is the first week when beginning,the fourth week when severity and the fourteenth week when becoming normal;The mean time of thrombocytopenia is the second week,the sixth week and the sixteenth week. Conclusion CIFN 15 μg as a monotherapy significantly improve end of treatment response rate in chronic hepatitis C patients. No serious adverse events were observed.